APRI (Aprinoia Therapeutics) Notes Receivable: $0.00 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Notes Receivable?

Aprinoia Therapeutics APRI Notes Receivable is $0.00 Mil as of Dec. 2023.

Aprinoia Therapeutics's Notes Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Aprinoia Therapeutics's quarterly Notes Receivable increased from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($0.66 Mil) but then stayed the same from Jun. 2023 ($0.66 Mil) to Dec. 2023 ($0.00 Mil).

Aprinoia Therapeutics Notes Receivable Related Terms

Aprinoia Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Notes Receivable Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Notes Receivable
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Notes Receivable 0.00 0.00 0.00 0.66 0.00

Aprinoia Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Aprinoia Therapeutics (APRI) has a Notes Receivable of $0.00 Mil as of Dec. 2023. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Notes Receivable too high?
Aprinoia Therapeutics' current Notes Receivable is $0.00 Mil.
How does Aprinoia Therapeutics' Notes Receivable compare to ?
Aprinoia Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Notes Receivable is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.